Core Insights - Pharvaris has published results from two Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, demonstrating the efficacy and safety of deucrictibant, a bradykinin B2 receptor antagonist, for managing hereditary angioedema (HAE) [1][2] Study Results - CHAPTER-1 study showed a statistically significant reduction in the occurrence of HAE attacks and improvements in disease control and health-related quality of life, with deucrictibant being well tolerated at both tested doses [3] - RAPIDe-1 study indicated a statistically significant reduction in the severity of HAE attack manifestations, along with reduced time to symptom relief and resolution, with deucrictibant well tolerated at all tested doses [4] Product Development - Deucrictibant is being developed in two formulations: an extended-release tablet for prophylactic treatment and an immediate-release capsule for on-demand treatment, aiming to provide a comprehensive approach to HAE management [8] - The company is preparing marketing authorization applications for the immediate-release capsule and is conducting a Phase 3 study (CHAPTER-3) for the extended-release tablet, with topline data expected in Q3 2026 [9] Industry Context - The use of bradykinin B2 receptor antagonism has been established as the standard-of-care for on-demand treatment of HAE attacks, with deucrictibant emerging as a potentially unique oral therapy for both prophylactic and acute treatment [5][2] - The concurrent publication of the study results in The Lancet Haematology adds to the scientific evidence supporting the management of bradykinin-mediated angioedema [5]

Summary of Pharvaris Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Focus**: Development of deucrictibant for treating Hereditary Angioedema (HAE) Recent Progress and Priorities - Pharvaris is preparing to file its first drug for acute treatment based on strong data from December 2025 - Ongoing prophy trial expected to have top-line readout in Q3 2026 - Enrollment in a pivotal trial for acquired angioedema is ongoing - Preparing for commercial launch and organizational ramp-up [4][11][19] Clinical Data Highlights - **RAPIDe-3 Trial Results**: - Primary endpoint (PGIC) achieved with deucrictibant relieving symptoms in approximately 1.28 hours compared to over 12 hours for placebo - New endpoint "End of Progression" showed patients stopped feeling worse in about 17.5 minutes - Complete symptom resolution achieved in less than 12 hours, outperforming standard care [8][9][10] Regulatory and Launch Preparations - NDA submission planned for the first half of 2026, with preparations on track - Pre-NDA meeting has already occurred, and the company is working towards a complete filing [11][13][17] Market Position and Strategy - The company anticipates a standard review from regulators, aiming for a potential launch in the first half of 2027 [17] - Emphasis on building visibility in the healthcare community through the "Deflate HAE" campaign to raise disease awareness [19][22] - The campaign aims to address the unmet need for effective treatments in the HAE patient community [22][24] Competitive Landscape - The oral on-demand treatment segment is expected to dominate, with a strong preference for oral therapies over injectables due to convenience [34][44] - The company believes that the profile of deucrictibant positions it favorably against existing treatments, particularly in terms of speed and efficacy [36][38] - There is a significant opportunity to switch patients from existing treatments to deucrictibant, especially as the oral segment grows [90][91] Prophylactic Opportunity - The CHAPTER-3 pivotal trial is progressing on track, with data expected in Q3 2026 [65] - The extended-release formulation is being developed alongside the immediate-release formulation, with distinct pharmacokinetic profiles [68][71] - The company aims for a broader label that includes normal C1 patients, addressing additional unmet medical needs [54][81] Financial Position - Cash balance reported at EUR 380 million as of Q3 2026, with a runway projected to the first half of 2027 [123] Conclusion - Pharvaris is strategically positioned to capitalize on the growing demand for oral therapies in the HAE market, with a strong focus on clinical data, regulatory preparations, and market awareness campaigns to support its upcoming product launches.

Core Insights - Pharvaris has published results from a non-interventional study assessing patient experiences during hereditary angioedema (HAE) attacks, which supports the inclusion of meaningful endpoints in clinical studies for on-demand treatment [1][2][4] Company Overview - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases, including HAE and acquired angioedema due to C1 inhibitor deficiency [1][9] - The company is preparing marketing authorization applications for its immediate-release capsule of deucrictibant as an on-demand treatment for HAE attacks, with a pivotal Phase 3 study ongoing for the extended-release tablet [9] Study Findings - The study utilized a mixed methods approach, combining quantitative real-time electronic patient-reported outcome (PRO) assessments during HAE attacks with qualitative post-attack interviews [3][4] - Key symptoms such as skin swelling, abdominal pain, and difficulty swallowing were identified as important by participants, with even small improvements considered meaningful [4][5] - The study validated the reliability and sensitivity of the Patient Global Impression of Change (PGI-C) and Angioedema symptom Rating scale (AMRA) instruments for assessing patient experiences during HAE attacks [4][6] Clinical Implications - The findings from the study are expected to inform the design of clinical trials for on-demand treatments of HAE attacks, including the hierarchy of endpoints in the Phase 3 RAPIDe-3 trial of deucrictibant [5][6] - The study reinforces the importance of patient-reported outcomes in guiding treatment decisions and developing new therapies for HAE [2][6]

Summary of Pharvaris Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Industry**: Hereditary Angioedema (HAE) therapeutics - **Focus**: Development of therapies for bradykinin-mediated angioedema, including prophylactic and on-demand treatment options [1][2][3] Core Points and Arguments Market Evolution - The HAE market has evolved significantly over the past 20 years, transitioning from a focus on managing attacks to controlling the disease [8][9] - Current market size for on-demand treatment is estimated at **$600 million** in the US, representing about **20%** of the total HAE market [29][46] - The market is expected to be dominated by oral therapies due to their simplicity and speed of treatment [29][31] Product Development and Clinical Trials - Pharvaris is developing **deucrictibant**, with Phase 3 data showing statistically significant results across all primary and secondary endpoints [16][17] - Key Phase 3 endpoint results include: - Time to initial symptom relief: **1.28 hours** - Time to stop attack progression: **17.5 minutes** - Time to complete symptom resolution: less than **12 hours** [16][17] - The company is also conducting a Phase 3 trial for prophylactic treatment (CHAPTER-3) with top-line data expected in Q3 of this year [54][56] Patient Experience and Market Strategy - The convenience of an oral treatment is emphasized as a significant factor for patients, allowing for immediate use during an attack [20][22] - The company aims to provide a therapy that not only alleviates symptoms but also enhances the quality of life for patients [61] - Pharvaris is building awareness in the HAE community through campaigns like "Deflate HAE" and is preparing for product launches [52][100] Competitive Landscape - The current competitive landscape includes products like **icatibant** and **Orladeyo**, with Pharvaris aiming to offer a more effective oral alternative [28][46][49] - The company believes that a successful launch of deucrictibant could shift market dynamics, potentially leading to a return to branded pricing for on-demand treatments [48][49] Financial Position and Future Outlook - Pharvaris has a strong cash position with **EUR 360 million** reported in Q3, providing a runway into the first half of 2027 [107][108] - Upcoming catalysts include the NDA filing for on-demand treatment and the potential for a joint filing for prophylactic treatment [103][104] Additional Important Insights - The company is exploring opportunities in acquired angioedema, which is currently underdiagnosed and represents about **10%** of the market [71][75] - There is a strategic advantage in offering both on-demand and prophylactic options, allowing for flexibility in patient treatment plans [82][85] - The company is focused on building relationships with healthcare providers to facilitate the adoption of their therapies [100][101]

Core Insights - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases, particularly hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][12] Clinical Data and Efficacy - The Phase 3 RAPIDe-3 study demonstrated that deucrictibant achieved rapid and sustained symptom relief for HAE attacks, with a median time to onset of symptom relief of 1.28 hours compared to over 12 hours for placebo [3][6] - Deucrictibant met all primary and secondary efficacy endpoints, with 90.4% of treated attacks achieving symptom relief within 12 hours, and a median time to complete resolution of 11.95 hours versus over 48 hours for placebo [3][6] - The long-term safety and efficacy of deucrictibant were supported by the Phase 2 CHAPTER-1 study, showing a reduction in attack rate from 2.18 attacks per month to 0.12 attacks per month over approximately three years [5][7] Quality of Life Improvements - Treatment with deucrictibant resulted in clinically meaningful improvements in health-related quality of life (HRQoL) and higher treatment satisfaction for participants over the long term [8] Novel Biomarker Development - Pharvaris has developed a kinin biomarker assay to measure bradykinin levels in plasma, which may aid in the characterization and management of bradykinin-mediated angioedema [10] Product Development and Regulatory Status - Deucrictibant is being developed in two formulations: an immediate-release capsule for on-demand treatment and an extended-release tablet for prophylactic use [11] - The company is preparing marketing authorization applications for the immediate-release capsule and is conducting a global pivotal Phase 3 study for the extended-release tablet, with topline data expected in Q3 2026 [12]

Summary of Pharvaris FY Conference Call Company Overview - **Company**: Pharvaris (NasdaqGS:PHVS) - **Focus**: Treatment of Hereditary Angioedema (HAE), a rare genetic condition characterized by painful and potentially fatal swelling attacks [4][5] Core Points and Arguments Company Background - Pharvaris was established 10 years ago, with a focus on addressing unmet needs in HAE treatment, particularly for an oral therapy option [4][6] - The company aims to develop deucrictibant, an oral B2 receptor antagonist, to provide a highly efficacious treatment for HAE and other forms of angioedema [7][8] Market Dynamics - The current market for HAE treatments is dominated by injectables, with approximately 63% of patients on long-term prophylaxis, representing about 80% of the market value [12][13] - The clinical guidelines suggest that ideally, HAE patients should never suffer from attacks, highlighting the need for effective prophylactic treatments [13] Clinical Data - The Phase 3 trial for deucrictibant in the on-demand setting showed significant results, with a primary endpoint met and all 11 secondary endpoints achieving statistical significance [16] - Key findings include: - Onset of symptom relief at 1.28 hours compared to 12 hours for placebo [17] - End of progression of the attack at 17 minutes, providing comfort to patients [17] - Faster complete resolution compared to standard care and recently approved oral therapies [19] Competitive Landscape - The oral therapy market is becoming increasingly competitive, with KalVista's EKTERLY recently launched. However, deucrictibant is positioned to differentiate itself through faster onset and resolution of symptoms [21][22] - The Phase 2 data for deucrictibant in the prophylactic setting showed an 84.5% attack reduction, comparable to injectable therapies [41] Regulatory and Commercial Strategy - Pharvaris plans to file for NDA in the first half of 2026, with a potential launch about a year later [20] - The company is expanding its Phase 3 studies to include a broader patient demographic and geographic range, which may mitigate risks associated with trial outcomes [45] Financial Outlook - The company has sufficient cash runway into the first half of 2027, with plans to ramp up commercial operations and team expansion [56][57] Additional Important Information - Pharvaris will present at the QUAD A conference, showcasing Phase 3 data and other significant findings, including a 92.3% attack reduction from an open-label extension study [53] - The company is also involved in community engagement, sponsoring events like the HAEA Foundation's 5K run [54] This summary encapsulates the key points discussed during the Pharvaris FY conference call, highlighting the company's strategic focus, clinical advancements, market positioning, and financial outlook.

Core Insights - Pharvaris is set to present pivotal Phase 3 data from the RAPIDe-3 study of deucrictibant for on-demand treatment of hereditary angioedema (HAE) attacks at the AAAAI 2026 Annual Meeting [1][2] - The company will also share final data from the Phase 2 CHAPTER-1 study and pharmacokinetic data of the extended-release formulation of deucrictibant [2] Presentation Details - Six abstracts have been accepted for poster presentation, with three featured during a special session [1] - Key presentations include: - A novel kinin biomarker assay for bradykinin-mediated angioedema [2] - Content validity of the Angioedema symptom rating scale (AMRA) [2] - Long-term prophylactic treatment results from the Phase 2 CHAPTER-1 study [2] - Results from the Phase 3 RAPIDe-3 study on oral deucrictibant for HAE attacks [2] - Long-term safety and efficacy results from the Phase 2 CHAPTER-1 study [2] - Sustained therapeutic exposure with the once-daily oral deucrictibant extended-release tablet [2] Company Overview - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases [4] - The company aims to provide therapies with injectable-like efficacy and the convenience of oral administration [4] - Pharvaris is preparing global marketing authorization applications for deucrictibant immediate-release capsules and is conducting a pivotal Phase 3 study for the extended-release tablet [4]

Core Insights - Pharvaris is focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases, particularly hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][14] - The company outlined its strategic priorities for 2026, emphasizing long-term prophylaxis and on-demand treatment of HAE attacks [3][4] Clinical Development - The pivotal Phase 3 study, RAPIDe-3, demonstrated that deucrictibant significantly reduced the median time to onset of symptom relief to 1.28 hours compared to placebo (p<0.0001) [5] - Topline data from the CHAPTER-3 study, assessing deucrictibant for prophylactic treatment of HAE attacks, is expected in the third quarter of 2026 [4][5] - The NDA dossier for deucrictibant's on-demand treatment of HAE attacks is on track for filing in the first half of 2026 [4][5] Financial and Operational Updates - Pharvaris has an estimated cash runway into the first half of 2027, indicating strong financial management [4][11] - The company was added to the Nasdaq Biotechnology Index in December 2025, reflecting its compliance with market capitalization and trading volume requirements [11] Upcoming Events - Pharvaris will participate in several investor conferences and medical congresses in early 2026, showcasing its ongoing clinical studies and findings [8][10][12]

Core Insights - Pharvaris N.V. (NASDAQ:PHVS) is highlighted as a promising small-cap stock with significant upside potential, receiving a Buy rating from Morgan Stanley with a price target of $41 and an Outperform rating from Oppenheimer with a raised target of $50 from $44 [1][2]. Group 1: Clinical Study Results - The pivotal RAPIDe-3 study demonstrated positive top-line results for deucrictibant, confirming its potential for on-demand treatment of HAE attacks, with a median time to onset of symptom relief of 1.28 hours, significantly faster than placebo [2]. - All secondary efficacy endpoints were achieved, including a median End of Progression time of 17.47 minutes and complete symptom resolution in a median of 11.95 hours, confirming the safety profile of deucrictibant across various HAE subtypes and attack severities [3]. Group 2: Future Plans - Pharvaris N.V. plans to use data from the pivotal Phase 3 study as the basis for marketing authorization applications, which are expected to be filed in the first half of 2026 [4].

Core Insights - Saturn V Capital Management has initiated a new position in Pharvaris N.V. (PHVS), acquiring 886,332 shares valued at approximately $22.1 million during the third quarter, indicating strong interest from a major hedge fund in the biotech sector [1][2]. Company Overview - Pharvaris N.V. is a clinical-stage biotechnology company focused on developing novel oral therapies for hereditary angioedema (HAE), a rare genetic disorder [6][9]. - The company has three pivotal programs underway: PHA121 (Phase II), PHVS416 (Phase II), and PHVS719 (Phase I), targeting both acute and prophylactic treatment needs [9][10]. - As of market close on the reporting date, Pharvaris shares were priced at $25.35, reflecting a 33% increase over the past year, outperforming the S&P 500, which rose by 12% in the same period [3][4]. Financial Metrics - Pharvaris has a market capitalization of $1.6 billion and reported a net income of -$163.7 million for the trailing twelve months (TTM) [4]. - The company had €329 million in cash on hand as of September 30, which is expected to finance operations into the first half of 2027, covering major data readouts [10]. Investment Implications - Saturn V's stake in Pharvaris represents about 4.9% of its 13F assets, aligning with the fund's focus on biotech investments and high-conviction clinical risks [3][11]. - Recent positive topline data from the RAPIDe-3 Phase 3 trial showed a median time to onset of symptom relief of 1.3 hours, highlighting the potential for future growth despite the company being pre-revenue [11][12].